Aurinia Pharmaceuticals Inc. (AUPH) · Oct 30, 2026 · Earnings

Aurinia earnings in line, but 2026 revenue guidance rises

In line — Revenue $83.7M vs ~$83.6M consensus; diluted EPS $0.23 vs ~$0.22

Aurinia’s Q3 earnings were broadly in line, while stronger LUPKYNIS sales support a higher 2026 revenue outlook.

Aurinia is a commercial-stage autoimmune company using LUPKYNIS to expand treatment of lupus nephritis while building aritinercept as its next pipeline asset; the latest public filing described LUPKYNIS sales growth and aritinercept development across multiple indications.

The quarter landed broadly where the market expected. Third-quarter revenue of $83.7 million was essentially in line with the published consensus of roughly $83.6 million, while diluted EPS of $0.23 was modestly above the roughly $0.22 estimate. That is a clean execution quarter, not a material earnings surprise.

Q3 2026Q3 2025Consensus
Total revenue (Financial Highlights)$83.7M (+13.9%)$73.5M~$83.6M
LUPKYNIS sales (Financial Highlights)$79.4M (+12.4%)$70.6M
Diluted EPS (Financial Highlights)$0.23$0.23~$0.22
Operating cash flow, nine months (Cash Flow statement)$131.5M (+46.1%)$90.0M
2026 total revenue guidance (Guidance)$325M–$330M$315M–$325M prior

LUPKYNIS remains the engine, with growth holding up rather than accelerating sharply. Product sales rose 12% year over year to $79.4 million, and nine-month sales reached $232.4 million. The company is still gaining lupus-nephritis penetration, but the quarter's growth rate was slower than the 19% reported in the second quarter, so the main takeaway is durability rather than a fresh step-change.

The meaningful upside is the raised revenue outlook. Aurinia lifted 2026 total revenue guidance to $325 million–$330 million from $315 million–$325 million, raising the midpoint by $7.5 million. It also narrowed product-sales guidance to $310 million–$315 million from $305 million–$315 million: the top end did not move, but the bottom end rose, showing greater confidence in the commercial base rather than a dramatic acceleration.

The balance sheet gives Aurinia room to keep funding the pipeline and returning capital. Cash, cash equivalents, restricted cash and investments totaled $486.9 million at quarter-end, while operating cash flow reached $131.5 million through nine months. That supports the newly initiated PRESERVE Phase 4 combination study and aritinercept development, although the filing gives no efficacy data yet; these programs remain investment stories, not validated growth drivers.

Bottom line: This was an in-line quarter with a modestly better outlook, not a major earnings beat. The business story is improving incrementally: LUPKYNIS growth remains dependable, cash generation is strong, and higher revenue guidance makes the setup modestly better than before, while the pipeline still awaits clinical proof.

What to watch next

Q4 earnings and full-year results, early 2027

Original filing on SEC EDGAR

More Aurinia Pharmaceuticals Inc. news

Aurinia earnings in line, but 2026 revenue guidance rises | AUPH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.